TOKYO, Jul 06 (Pulse News Wire) – Ribomic INC. (4591.T), represented by President Yoshikazu Nakamura, entered into a business partnership agreement with Fuji Film Toyama Chemical Co., Ltd., led by President Mitsuhiko Sato, to develop CDMO services utilizing aptamer-modified lipid nanoparticles (LNPs).
The collaboration aims to enhance the delivery efficiency and target specificity of nucleic acid drugs through advanced aptamer technology. Under the agreement, RiboMick will non-exclusively supply aptamers while Fuji Film Toyama Chemical will handle LNP manufacturing and related processes. This strategic alliance allows for the integrated provision of aptamer-modified LNPs as part of their CDMO service portfolio. The partnership seeks to address growing market demands for targeted drug delivery systems, particularly in areas such as in vivo CAR-T therapies and genetic disease treatments.
Fuji Film Toyama Chemical, established on December 05, 1968, operates out of 2-14-1 Kanematsu Building, with a capital of ¥100 million. It specializes in mRNA synthesis and LNP formulation, leveraging advanced synthetic and nanodispersion technologies to ensure high safety and delivery efficacy. The firm has extensive experience supplying LNPs to academic institutions and pharmaceutical companies, along with a track record in clinical trial drug production. Looking ahead, RiboMick expects this partnership to bolster its long-term profitability in the drug discovery support sector.
An assessment of potential impacts on fiscal 2027 performance is ongoing, and any significant findings will be promptly disclosed.
🟢 Confidence: High AI-translated content.